Dr. Ching Y. Voss, MD

Specialty: Holistic and Integrative Medicine, Board Certified in Laboratory Medicine and Transfusion Medicine

Practice Philosophy: Knowing the perspectives from both modern medical science and the healing power of nature brought me where I am today. My favorite quotations are: "Treat others as you want to be treated," and "Let food be thy medicine and medicine be thy food."

Areas of Focus: Holistic primary care,  Integrative cancer care, Insulin Potentiation Therapy (IPT, low dose chemotherapy), diabetes, pre-diabetes and insulin resistance,  hypertension, depression, IV clearances, general wellness exams, chronic disease management and acute sick care.

• Review and consult on diagnoses of cancer; implementing protocols at NIHA using integrative cancer therapies (IPT insulin potentiation low dose chemotherapy) combined with other holistic and conventional medicine approaches to improve the outcome and quality of life for cancer patients.*
• Integrate conventional medicine and alternative medicine including traditional Chinese herbal medicine together to gain a better understanding and management of various medical conditions for disease prevention and treatments.
• Provide evidence-based therapeutic procedures for blood purification and immune modulation to correct the underlying pathologies in various diseases including but not limited to autoimmune disorders, cancer, refractory hyperlipidemia, blood circulation problems, depression and other neurological conditions.

About

Dr. Voss is devoted and dedicated to bring the best of Western Medicine and Eastern Medicine together. She obtained her medical education and clinical work experience in both China and the United States. She completed her residency and fellowship training at the University of Wisconsin, Madison. She was a recipient of Intramural Research Training Awards from the Clinical Center, National Institutes of Health (NIH). She has over 30 years combined experience as an internist, medical researcher, pathologist and transfusion medicine specialist. She has worked together with internationally renowned physicians and scientists, and has published articles regarding innovative therapies for cancers and autoimmune diseases. From her personal experience in overcoming pre-diabetes and depression, she now devotes her efforts to her integrative medical practice for the benefit of more people in our community.

*Dr. Voss has been involved in cancer patient care as a pathologist and transfusion medicine specialist but is not an oncologist.

Author, Selected Publications:

Ching Y. Voss, Terry J. Fry, Max J. Coppes and Morris A. Blajchman:  Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis.  Transfusion Medicine Reviews, 24: 22-32, 2010

Ching Y. Voss, S Deola, TA Fleisher, FM Marincola:  Increased Effector/target Cell Binding Due to HLA Restricted Specific Antigen Recognition.  Immunologic Research, 45:13-24, 2009

Friedlander SL, Dooms KT, Seroogy CM, Voss CY, Agger WA, Zhang K, Bleesing J, Filipvich AH: Adolescent Presentation of X-linked Lymphoproliferative Disease. Annals of Allergy, Asthma & Immunology, 100: 398-400, 2008

S Deola, MC Panelli, D Maric, S Selleri, NI Dmitrieva, CY Voss, Harvey Klein, David Stroncek, Ena Wang, and Francesco M. Marincola:  Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions.  The Journal of Immunology, 180: 1362-1372, 2008

Ching Y. Voss, Mark R. Albertini, and James S. Malter: Dendritic Cell-based Immunotherapy for Cancer and Relevant Challenges for Transfusion Medicine (Review).  Transfusion Medicine Reviews, 18:189-202, 2004.

ZQ Ye, P Qiu, JK Burkholder, J Turner, J Culp, T Roberts, NT Shahidi and NS Yang: Cytokine Transgene Expression and Promoter Usage in Primary CD34+ Cells Using Particle-Mediated Gene Delivery.  Human Gene Therapy, 9:2197-2205, 1998.

ZQ Ye, JK Burkholer, P Qiu, JC Schultz, NT Shahidi and NS Yang: Establishment of an Adherent Cell Feeder Layer from Human Umbilical Cord Blood for Support of Long-term Hematopoietic Progenitor Cell Growth.  Proceedings of the National Academy of Sciences U.S.A., 91:12140-12144, 1994.